You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Whole Brain Nanoscale Preservation Imaging

    SBC: Nectome Inc.            Topic: 101

    Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Using Magnetic Levitation for Non-Destructive Detection of Defective and Counterfeit Materiel

    SBC: Nano Terra, Inc.            Topic: DLA15C001

    The introduction of substandard or counterfeit materials into the DoD supply chain can have extremely expensive, and potentially life threatening, consequences. Current techniques used to detect nonconforming materiel can be destructive (e.g., manual sectioning and inspection of a part), time consuming and expensive (e.g., micro-computed tomography, ultrasound), or provide only limited informatio ...

    STTR Phase I 2016 Department of DefenseDefense Logistics Agency
  3. Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAV

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery approaches that are cumbersome to apply Consequently we have considered the u ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases

    SBC: ARISAN THERAPEUTICS INC            Topic: NIAID

    Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great impor ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. T SS needle protein inhibitors for the treatment of P aeruginosa infection

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Tribosupplementation of Injured Joints

    SBC: TRIBOLOGICS, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Joint injury is a well established risk factor in the pathogenesis of post-traumatic osteoarthritis (PTOA). In particular, patients with meniscal tears are at high risk for early PTOA. Chondroprotection of the joint surface is mediated by lubricin, a large glycoprotien which forms a lubricating nanofilm on the cartilage surface and provides anti-adhesion via st ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Topical Therapeutic to Promote Healing of Chronic Wounds

    SBC: Phoenicia Biosciences, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is defined as a wound that does not show signs of significant healing, or progresses, after use of topical/surgical treatment measures for six months. Non-healing wounds affect 6.5 million patients, aff ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutics for inflammatory bowel disease from the microbiome

    SBC: SYMBIOTIX BIOTHERAPIES, INC.            Topic: 300

    PROJECT SUMMARY ABSTRACT Interactions between the gut microbiome and the immune system have been linked to inflammatory bowel disease IBD IBD is a chronic and progressive gastrointestinal disease characterized by uncontrolled activation of the intestinal immune system resulting in severe medical complications affecting over million patients in the United States It is a disease of high u ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

    SBC: DYNAVAX TECHNOLOGIES CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): Hepatic fibrosis (HF) is a major health problem leading to cirrhosis and death. There is currently no pharmacological treatment for HF, and liver transplantation is unable to meet the needs of all patients afflicted with HF. We have shown that chronic liver injury involves the activation of Toll-like receptor 7 (TLR7) and TLR9. We further demonstrated that the ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government